Virax Biolabs Group Limited Ordinary Shares (VRAX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $823,940
Last updated: Nov 17, 2026 at 11:04 AM ET
Virax Biolabs Group Limited Ordinary Shares (VRAX) Financials: Revenue, Profit and Cash Flow
Virax Biolabs Group Limited Ordinary Shares reported revenue of $12.42K for the fiscal year ended Mar 31, 2026, up 96.2% from the year before. That year, net income was -$5.02M with a net margin of -40439.1%, operating cash flow was -$4.62M and free cash flow was -$4.88M. The quarter ended Jun 30, 2026 had revenue of $12.42K and net income of -$5.02M.
Revenue and Margins
Over the 6 years to Mar 2026, revenue fell from $99.88K, a compound annual decline of 29.4%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Mar 2026 | $12.42K | +96.2% | 61.9% | -51515.2% | -40439.1% |
| Mar 2025 | $6.33K | -96.0% | -838.2% | -97344.8% | -95739.2% |
| Mar 2024 | $156.42K | +1727.1% | 32.3% | -4153.3% | -4304.8% |
| Mar 2023 | $8.56K | N/A | -15.9% | -66963.7% | -63748.3% |
| Mar 2022 | $0 | -100.0% | N/A | N/A | N/A |
| Mar 2021 | $123.82K | +24.0% | -7.6% | -520.5% | -525.8% |
| Mar 2020 | $99.88K | N/A | 45.8% | -652.1% | -802.1% |
Income Statement
In the fiscal year ended Mar 2026, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $12.42K | $6.33K | $156.42K | $8.56K | $0 | $123.82K | $99.88K |
| Cost of revenue | $4.73K | $59.40K | $105.83K | $9.93K | $0 | $133.25K | $54.13K |
| Gross profit | $7.69K | -$53.07K | $50.59K | -$1.36K | $0 | -$9.43K | $45.75K |
| Research and development | $3.74M | $1.78M | $1.56M | $397.11K | $433.74K | $120.22K | $87.00K |
| Operating income | -$6.40M | -$6.16M | -$6.50M | -$5.73M | -$1.73M | -$644.54K | -$651.24K |
| Net income | -$5.02M | -$6.06M | -$6.73M | -$5.46M | -$1.71M | -$650.98K | -$801.13K |
| EBITDA | -$5.43M | -$5.80M | N/A | -$5.44M | -$750 | $266 | $2.47K |
Quarterly
| Line item | Jun 2026 | Sep 2025 | Jun 2025 | Sep 2024 | Jun 2024 | Sep 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.42K | $1.61K | $1.38K | $4.95K | $79.92K | $76.50K | $2.80K | $2.80K | $5.76K | -$92.86K | -$92.86K | $30.95K |
| Gross profit | $7.69K | -$215.41K | -$46.59K | -$6.47K | $40.07K | $10.52K | -$1.48K | -$1.48K | $118 | -$192.81K | N/A | N/A |
| Operating income | -$6.40M | -$2.59M | -$3.28M | -$2.88M | -$3.79M | -$2.71M | -$4.29M | -$4.29M | -$1.44M | -$1.17M | N/A | N/A |
| Net income | -$5.02M | -$2.34M | -$3.30M | -$2.76M | -$3.82M | -$2.91M | -$4.01M | -$4.01M | -$1.44M | -$1.16M | -$427.39K | N/A |
Balance Sheet
As of Mar 2026, cash and equivalents exceeded short-term debt of $109.58K by $6.33M.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Total assets | $8.32M | $6.43M | $5.48M | $9.81M | $48.71K | $94.12K | $22.61K |
| Current assets | $6.83M | $4.89M | $4.38M | $9.63M | $48.71K | $39.62K | $22.61K |
| Cash and equivalents | $6.44M | $4.23M | $3.59M | $9.35M | $21.76K | $17.62K | $22.61K |
| Total liabilities | $989.83K | $964.75K | $345.19K | $908.40K | $1.25M | $871.43K | $1.24M |
| Short-term debt | $109.58K | $85.46K | $47.95K | $146.25K | $3.76K | $179.48K | $759.37K |
| Shareholder equity | $7.58M | $5.70M | $5.37M | $9.13M | -$974.58K | -$596.18K | -$1.06M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 | Sep 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $8.32M | $8.32M | $5.72M | $6.43M | $6.43M | $9.44M | $5.48M | $5.48M | $7.03M | $9.81M | $9.81M | $5.30M |
| Total liabilities | $989.83K | $989.83K | $641.52K | $964.75K | $964.75K | $1.03M | $345.19K | $345.19K | $919.05K | $908.40K | $908.40K | $1.14M |
| Cash and equivalents | $6.44M | $6.44M | $3.35M | $4.23M | $4.23M | $7.29M | $3.59M | $3.59M | $5.11M | $9.35M | $9.35M | $4.57M |
| Shareholder equity | $7.58M | $7.58M | $5.31M | $5.70M | $5.70M | $8.64M | $5.37M | $5.37M | $6.33M | $9.13M | $9.13M | $4.39M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Mar 2026.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.62M | -$4.56M | -$6.25M | -$4.18M | -$809.07K | -$590.19K | -$744.61K |
| Capital expenditures | $255.83K | $603.89K | $1.16M | $178.40K | $0 | $0 | $0 |
| Free cash flow | -$4.88M | -$5.17M | -$7.41M | -$4.36M | -$809.07K | -$590.19K | -$744.61K |
| Investing cash flow | -$255.83K | -$603.89K | -$1.16M | -$178.40K | -$178.40K | -$178.40K | -$178.40K |
| Financing cash flow | $7.09M | $5.81M | $1.65M | $13.69M | $813.21K | $585.20K | $704.64K |
Quarterly
| Line item | Jun 2026 | Sep 2025 | Jun 2025 | Sep 2024 | Jun 2024 | Sep 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.62M | -$2.92M | -$2.45M | -$1.92M | -$2.79M | -$3.46M | -$1.88M | -$1.88M |
| Capital expenditures | $255.83K | $141.50K | $355.89K | $248.00K | $459.92K | $708.18K | $178.40K | $178.40K |
| Free cash flow | -$4.88M | -$3.06M | -$2.81M | -$2.17M | -$3.25M | -$4.17M | -$2.06M | -$2.06M |
Frequently Asked Questions About VRAX
What is Virax Biolabs Group Limited Ordinary Shares' annual revenue?
Virax Biolabs Group Limited Ordinary Shares reported revenue of $12.42K for the fiscal year ended Mar 31, 2026.
How fast is Virax Biolabs Group Limited Ordinary Shares' revenue growing?
Revenue was up 96.2% for the fiscal year ended Mar 31, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 13.2%.
Is Virax Biolabs Group Limited Ordinary Shares profitable?
No. Virax Biolabs Group Limited Ordinary Shares reported net income of -$5.02M for the fiscal year ended Mar 31, 2026, with a net margin of -40439.1%.
How much free cash flow does VRAX generate?
For the fiscal year ended Mar 31, 2026, operating cash flow of -$4.62M minus capital expenditures of $255.83K produced free cash flow of -$4.88M.
How much debt does Virax Biolabs Group Limited Ordinary Shares have?
The balance sheet dated Mar 31, 2026 reported short-term debt of $109.58K and cash and equivalents of $6.44M.
VRAX pages: Overview, Financials